Radiotherapy-induced Lung Toxicity: Risk Factors and Prevention Strategies

Anticancer Research

Volumn 23, Issue 6 D, 2003, Pages 4991-4998

  Nieder, Carsten ^a   Jeremic, Branislav ^a   Astner, Sabrina ^a   Molls, Michael ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

Lung cancer; Lung fibrosis; Pneumonitis; Radiotherapy; Side effects

Indexed keywords

AMIFOSTINE; BASIC FIBROBLAST GROWTH FACTOR; CARVEDILOL; CD40 LIGAND MONOCLONAL ANTIBODY; CELL ADHESION MOLECULE; COPPER ZINC SUPEROXIDE DISMUTASE; CYTOKINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GROWTH FACTOR; INDOMETACIN; N(G) NITROARGININE METHYL ESTER; PENICILLAMINE; PENTOXIFYLLINE; PERINDOPRIL TERT BUTYLAMINE; RECOMBINANT INTERLEUKIN 11;

CANCER RADIOTHERAPY; CLINICAL RESEARCH; CLINICAL TRIAL; CYTOLOGY; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG MECHANISM; DRUG TISSUE LEVEL; HUMAN; LUNG CANCER; LUNG FIBROSIS; MOLECULAR BIOLOGY; NONHUMAN; PREDICTION; PRIORITY JOURNAL; RADIATION PNEUMONIA; RADIOSENSITIVITY; REVIEW; RISK FACTOR; SHORT SURVEY; TREATMENT OUTCOME;

ANIMALS; HUMANS; LUNG; LUNG NEOPLASMS; RADIATION PNEUMONITIS; RADIOTHERAPY; RISK FACTORS;

EID: 0842278704     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Short Survey

References (54)

1. Sawyer TE and Bonner JA: Postoperative irradiation in non-small cell lung cancer. Semin Radiat Oncol 10: 280-288, 2000.
2. Vujaskovic Z, Marks LB and Anscher MS: The physical parameters and molecular events associated with radiation-induced lung toxicity. Semin Radiat Oncol 10: 296-307, 2000.
3. Tsujino K, Hirota S, Endo M et al: Predictive value of dose-volume histogram parameters for predicting radiation pneumonitis after concurrent chemoradiation for lung cancer. Int J Radiat Oncol Biol Phys 55: 110-5, 2003.
4. Wang JY, Chen KY, Wang JT et al: Outcome and prognostic factors for patients with non-small-cell lung cancer and severe radiation pneumonitis. Int J Radiat Oncol Biol Phys 54: 735-741, 2002.
5. Monson JM, Stark P, Reilly JJ et al: Clinical radiation pneumonitis and radiographic changes after thoracic radiation therapy for lung carcinoma. Cancer 82: 842-850, 1998.
6. Bjermer L, Franzen L, Littbrand B et al: Effects of smoking and irradiated volume on inflammatory response in the lung of irradiated breast cancer patients evaluated with bronchoalveolar lavage. Cancer Res 50: 2027-2030, 1990.
7. Johansson S, Bjermer L, Franzen L et al: Effects of ongoing smoking on the development of radiation-induced pneumonitis in breast cancer and oesophagus cancer patients. Radiother Oncol 49: 41-47, 1998.
8. Geara FB, Komaki R, Tucker SL et al: Factors influencing the development of lung fibrosis after chemoradiation for small cell carcinoma of the lung: evidence for inherent interindividual variation. Int J Radiat Oncol Biol Phys 41: 279-286, 1998.
9. Dileto CL and Travis EL: Fibroblast radiosensitivity in vitro and lung fibrosis in vivo: comparison between a fibrosis-prone and fibrosis-resistant mouse strain. Radiat Res 146: 61-67, 1996.
10. Hernando ML, Marks LB, Bentel GC et al: Radiation-induced pulmonary toxicity: a dose-volume histogram analysis in 201 patients with lung cancer. Int J Radiat Oncol Biol Phys 51: 650-659, 2001.
11. Yorke ED, Jackson A, Rosenzweig KE et al: Dose-volume factors contributing to the incidence of radiation pneumonitis in non-small-cell lung cancer patients treated with three-dimensional conformal radiation therapy. Int J Radiat Oncol Biol Phys 54: 329-339, 2002.
12. Chen Y, Williams J, Ding I et al: Radiation pneumonitis and early circulatory cytokine markers. Semin Radiat Oncol 12 Suppl 1: 26-33, 2002.
13. Anscher MS, Marks LB, Shafman TD et al: Using plasma transforming growth factor beta-1 during radiotherapy to select patients for dose escalation. J Clin Oncol 19: 3758-3765, 2001.
14. Fu XL, Huang H, Bentel G et al: Predicting the risk of symptomatic radiation-induced lung injury using both the physical and biologic parameters V(30) and transforming growth factor beta. Int J Radiat Oncol Biol Phys 50: 899-908, 2001.
15. Kong FM, Anscher MS, Sporn TA et al: Loss of heterozygosity at the mannose 6-phosphate insulin-like growth factor 2 receptor (M6P/IGF2R) locus predisposes patients to radiation-induced lung injury. Int J Radiat Oncol Biol Phys 49: 35-41, 2001.
16. Senan S, Burgers S, Samson MJ et al: Can elective nodal irradiation be omitted in stage III non-small-cell lung cancer? Analysis of recurrences in a phase II study of induction chemotherapy and involved-field radiotherapy. Int J Radiat Oncol Biol Phys 54: 999-1006, 2002.
17. Rosenzweig KE, Sim SE, Mychalczak B et al: Elective nodal irradiation in the treatment of non-small-cell lung cancer with three-dimensional conformal radiation therapy. Int J Radiat Oncol Biol Phys 50: 681-685, 2001.
18. van Sornsen de Koste JR, Lagerwaard FJ, Schuchhard-Schipper RH et al: Dosimetric consequences of tumor mobility in radiotherapy of stage I non-small cell lung cancer - an analysis of data generated using 'slow' CT scans. Radiother Oncol 61: 93-99, 2001.
19. Harada T, Shirato H, Ogura S et al: Real-time tumor-tracking radiation therapy for lung carcinoma by the aid of insertion of a gold marker using bronchofiberscopy. Cancer 95: 1720-1727, 2002.
20. Seppenwoolde Y, Engelsman M, De Jaeger K et al: Optimizing radiation treatment plans for lung cancer using lung perfusion information. Radiother Oncol 63: 165-177, 2002.
21. Vanuytsel LJ, Vansteenkiste JF, Stroobants SG et al: The impact of (18)F-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) lymph node staging on the radiation treatment volumes in patients with non-small cell lung cancer. Radiother Oncol 55: 317-324, 2000.
22. Erdi YE, Rosenzweig K, Erdi AK et al: Radiotherapy treatment planning for patients with non-small cell lung cancer using positron emission tomography (PET). Radiother Oncol 62: 51-60, 2002.
23. Rosenzweig KE, Hanley J, Mah D et al: The deep inspiration breath-hold technique in the treatment of inoperable non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 48: 81-87, 2000.
24. Wulf J, Hadinger U, Oppitz U et al: Stereotactic radiotherapy of targets in the lung and liver. Strahlenther Onkol 177: 645-655, 2001.
25. Nagata Y, Negoro Y, Aoki T et al: Clinical outcomes of 3D conformal hypofractionated single high-dose radiotherapy for one or two lung tumors using a stereotactic body frame. Int J Radiat Oncol Biol Phys 52: 1041-1046, 2002.
26. Nutting CM, Bedford JL, Cosgrove VP et al: A comparison of conformal and intensity-modulated techniques for oesophageal radiotherapy. Radiother Oncol 61: 157-163, 2001.
27. Graham MM, Evans ML, Dahlen DD et al: Pharmacological alteration of the lung vascular response to radiation. Int J Radiat Oncol Biol Phys 19: 329-339, 1990.
28. Olejar T, Pouckova P and Zadinova M: Butylaminiperindopril decreases transforming growth factor-beta 1 messenger RNA production in lungs of C57B16 mice after low-dose whole-body irradiation. Drugs Exp Clin Res 26: 113-117, 2000.
29. Molteni A, Moulder JE, Cohen EF et al: Control of radiation-induced pneumopathy and lung fibrosis by angiotensin-converting enzyme inhibitors and an angiotensin II type 1 receptor blocker. Int J Radiat Biol 76: 523-532, 2000.
30. Wang LW, Fu XL, Clough R et al: Can angiotensin-converting enzyme inhibitors protect against symptomatic radiation pneumonitis? Radiat Res 153: 405-410, 2000.
31. Fleckenstein J, Nestle U, Walter K et al: Influence of ACE-inhibitors on the risk of radiation-induced lung injury in patients with lung cancer (Abstract). Radiother Oncol 56 Suppl 1: S130, 2000.
32. Jonsson OE, Bjermer L, Denekamp J et al: Perivascular cell protection in vivo and increased cell survival in vitro by the antihypertensive agent carvedilol following radiation. Eur J Cancer 35: 1268-1273, 1999.
33. Rube CE, Wilfert F, Uthe D et al: Modulation of radiation-induced tumour necrosis factor alpha (TNF-alpha) expression in the lung tissue by pentoxifylline. Radiother Oncol 64: 177-187, 2002.
34. Ward WF, Kim YT, Molteni A et al: Pentoxifylline does not spare acute radiation reactions in rat lung and skin. Radiat Res 129: 107-111, 1992.
35. Kwon HC, Kim SK, Chung WK et al: Effect of pentoxifylline on radiation response of non-small cell lung cancer: a phase III randomized multicenter trial. Radiother Oncol 56: 175-179, 2000.
36. Vujaskovic Z, Feng QF, Rabbani ZN et al: Assessment of the protective effect of amifostine on radiation-induced pulmonary toxicity. Exp Lung Res 28: 577-590, 2002.
37. Vujaskovic Z, Feng QF, Rabbani ZN et al: Radioprotection of lungs by amifostine is associated with reduction in profibrogenic cytokine activity. Radiat Res 157: 656-660, 2002.
38. Lockhart SP: Inhaled thiol and phosphorothiol radioprotectors rail to protect the mouse lung. Radiother Oncol 19: 187-191, 1990.
39. Koukourakis MI, Romanidis K, Froudarakis M et al: Concurrent administration of Docetaxel and Stealth liposomal doxorubicin with radiotherapy in non-small cell lung cancer: excellent tolerance using subcutaneous amifostine for cytoprotection. Br J Cancer 87: 385-392, 2002.
40. Antonadou D: Radiotherapy or chemotherapy followed by radiotherapy with or without amifostine in locally advanced lung cancer. Semin Radiat Oncol 12 Suppl 1: 50-58, 2002.
41. Komaki R, Lee JS, Kaplan B et al: Randomized phase III study of chemoradiation with or without amifostine for patients with favorable performance status inoperable stage II-III non-small cell lung cancer: preliminary results. Semin Radiat Oncol 12 Suppl 1: 46-49, 2002.
42. Lindegaard JC and Grau C: Has the outlook improved for amifostine as a clinical radioprotector? Radiother Oncol 57: 113-118, 2000.
43. Ward HE, Kemsley L, Davies L et al: The effect of steroids on radiation-induced lung disease in the rat. Radiat Res 136: 22-28, 1993.
44. Milas L, Nishiguchi I, Hunter N et al: Radiation protection against early and late effects of ionizing irradiation by the prostaglandin inhibitor indomethacin. Adv Space Res 12: 265-271, 1992.
45. Adawi A, Zhang Y, Baggs R et al: Blockade of CD40-CD40 ligand interactions protects against radiation-induced pulmonary inflammation and fibrosis. Clin Immunol Immunopathol 89: 222-230, 1998.
46. Breuer R, Tochner Z, Conner MW et al: Superoxide dismutase inhibits radiation-induced lung injury in hamsters. Lung 170: 19-29, 2000.
47. Epperly MW, Sikora CA, DeFilippi SJ et al: Pulmonary irradiation-induced expression of VCAM-1 and ICAM-1 is decreased by manganese superoxide dismutase-plasmid/liposome (MnSOD-PL) gene therapy. Biol Blood Marrow Transplant 8: 175-187, 2002.
48. Hallahan DE, Geng L and Shyr Y: Effects of intercellular adhesion molecule 1 (ICAM-1) null mutation on radiation-induced pulmonary fibrosis and respiratory insufficiency in mice. J Natl Cancer Inst 94: 733-741, 2002.
49. Khan MA, Van Dyk J, Yeung IWT and Hill RP: Partial volume rat lung irradiation: assessment of early DNA damage in different lung regions and effect of radical scavengers. Radiother Oncol 66: 95-102, 2003.
50. Redlich CA, Gao X, Rockwell S et al: IL-11 enhances survival and decreases TNF production after radiation-induced thoracic injury. J Immunol 157: 1705-1710, 1996.
51. Fuks Z, Alfieri A and Haimovitz-Friedman A: Intravenous bFGF protects the lung but not mediastinal organs against radiation-induced apoptosis in vivo. Cancer J Sci Am 1: 62-72, 1995.
52. Tee PG and Travis EL: Basic fibroblast growth factor does not protect against classical radiation pneumonitis in two strains of mice. Cancer Res 55: 298-302, 1995.
53. Oetzel D, Schraube P, Hensley F et al: Estimation of pneumonitis risk in three-dimensional treatment planning using dose-volume histogram analysis. Int J Radiat Oncol Biol Phys 33: 455-460, 1995.
54. Graham MV, Purdy JA, Emami B et al: Clinical dose-volume histogram analysis for pneumonitis after 3D treatment for non-small cell lung cancer (NSCLC). Int J Radiat Oncol Biol Phys 45: 323-329, 1999.